Kearney Alan, Halleran Ciaran, Walsh Elaine, Byrne Derina, Haugh Jennifer, Sahm Laura J
Pharmacy Department, Mercy University Hospital, Cork T12 WE28, Ireland.
Department of General Practice, School of Medicine, University College Cork, Cork T12 YN60, Ireland.
Pharmacy (Basel). 2017 Oct 27;5(4):60. doi: 10.3390/pharmacy5040060.
Pharmacist-led medication reviews in hospitals have shown improvement in patient outcomes. The aim of this study is to describe the prevalence and nature of pharmacist interventions (PIs) following a medication review in an Irish teaching hospital. PIs were recorded over a six-month period in 2015. PIs were assessed by a panel of healthcare professionals ( = 5) to estimate the potential of adverse drug events (ADEs). Descriptive statistics were used for the variables and the chi square test for independence was used to analyse for any association between the variables. Of the 1216 patients (55.8% female; median age 68 years (interquartile range 24 years)) who received a medication review, 313 interventions were identified in 213 patients. 412 medicines were associated with PIs, of which drugs for obstructive airway disease ( = 82), analgesics ( = 56), and antibacterial products for systemic use ( = 50) were the most prevalent. A statistically significant association was found between PI and patient's age ≥65 years ( = 0.000), as well as female gender ( = 0.037). A total of 60.7% of the PIs had a medium or high likelihood of causing an ADE. Pharmacist-led medication review in a hospital setting prevented ADEs. Patients ≥65 years of age and female patients benefited the most from the interventions.
医院里由药剂师主导的用药评估已显示出患者治疗效果有所改善。本研究旨在描述爱尔兰一家教学医院进行用药评估后药剂师干预措施(PI)的发生率及性质。2015年期间对PI进行了为期六个月的记录。由一组医疗专业人员(n = 5)对PI进行评估,以估计药物不良事件(ADE)的可能性。对变量使用描述性统计,对独立性使用卡方检验来分析变量之间的任何关联。在接受用药评估的1216名患者中(女性占55.8%;年龄中位数68岁(四分位间距24岁)),在213名患者中识别出313项干预措施。412种药物与PI相关,其中阻塞性气道疾病用药(n = 82)、镇痛药(n = 56)和全身用抗菌产品(n = 50)最为常见。在PI与患者年龄≥65岁(p = 0.000)以及女性(p = 0.037)之间发现了具有统计学意义的关联。总共60.7%的PI导致ADE的可能性为中等或高。医院环境中由药剂师主导的用药评估预防了ADE。年龄≥65岁的患者和女性患者从干预措施中受益最大。